Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue (2010 - 2026)

Lineage Cell Therapeutics' Non-Current Deffered Revenue history runs 16 years deep, the most recent figure standing at $13.0 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 4.5% year-over-year to $13.0 million in Q1 2026; TTM through Mar 2026 was $13.0 million, a 4.5% decrease from a year earlier, with the FY2025 full-year figure at $12.4 million, down 14.25% from the prior year.
• Non-Current Deffered Revenue advanced to $13.0 million in Q1 2026 per LCTX's latest filing, from $12.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $30.8 million in Q1 2022 and bottomed at $12.4 million in Q4 2025.
• The 5-year median for Non-Current Deffered Revenue is $18.5 million (2024), against an average of $19.3 million.
• Across the five-year window, Non-Current Deffered Revenue plunged 32.58% in 2023 and dropped 4.5% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $27.7 million in 2022, then slumped by 32.58% to $18.7 million in 2023, then slipped by 22.79% to $14.4 million in 2024, then dropped by 14.25% to $12.4 million in 2025, then advanced by 5.03% to $13.0 million in 2026.
• Per Business Quant, the three latest LCTX Non-Current Deffered Revenue figures stand at $13.0 million (Q1 2026), $12.4 million (Q4 2025), and $12.5 million (Q3 2025).